ArticleBMC pregnancy and childbirth2025
Placental proteomic signatures of preterm birth, gestational age, and birthweight.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPreterm birth and low birthweight are leading contributors to infant morbidity and mortality, yet underlying mechanisms remain poorly understood. Proteomics can provide insights into biological pathways that may be targets for prevention and reveal predictive markers of at-risk pregnancies. The placenta plays a critical role in parturition, yet few studies have investigated proteomic signatures in the placenta associated with birth outcomes.
methodsUsing untargeted, mass spectrometry-based label-free proteomics, 1,221 proteins were quantified in placental samples from 99 participants in the Conditions Affecting Neurocognitive Development and Learning in Early Childhood (CANDLE) study. Associations of placental proteomics with binary spontaneous preterm birth, continuous gestational age at birth, and birthweight-for-gestational age z-scores were evaluated via differential abundance analysis, pathway enrichment, and principal component analysis (PCA) adjusting for numerous potential confounders. Sparse partial least squares discriminant analysis (sPLS-DA) was employed in a classification analysis to predict preterm versus term birth using the placental proteomics data.
resultsPreterm birth was associated with expression of 295 proteins and 15 molecular pathways, while gestational age was associated with expression of 367 proteins and 28 molecular pathways. Among the proteins significantly associated with either outcome, 264 (72%) overlapped. Proteins most strongly associated with both birth timing measures included Steryl-sulfatase (STS; preterm birth: LogFC = 2.08, FDR < 0.0001; gestational age at birth: LogFC= -0.57, FDR < 0.000001) and Collagen alpha-2(I) chain (COL1A2; preterm birth: LogFC= -2.11, FDR < 0.001; gestational age at birth: LogFC = 0.49, FDR < 0.0001). No associations were identified with birthweight z-scores. Proteins with the strongest links to preterm birth were major contributors to variance explained in PCA, and four of ten retained PCs were significantly associated with preterm birth. The top component in sPLS-DA classified preterm birth with 86.9% accuracy using 30 proteins, while the optimal sPLS-DA solution retaining three components classified preterm birth with 87.7% accuracy using 120 proteins.
conclusionsMany of the top proteins and molecular pathways associated with birth timing measures have been previously implicated in birth outcomes and pregnancy complications, and point to mechanisms including energy production, inflammation, and oxidative stress that may drive these risks. These proteins may serve as targets in future mechanistic and therapeutic research. Proteins identified through sPLS-DA demonstrated high accuracy in distinguishing preterm from term birth, pointing to potential targets for clinical screening tools, but necessitating validation in independent studies and more accessible biospecimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.